<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33329408</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.</ArticleTitle>
        <Pagination>
          <StartPage>615993</StartPage>
          <MedlinePgn>615993</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">615993</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2020.615993</ELocationID>
        <Abstract>
          <AbstractText>GO is the most frequent extrathyroidal manifestation of Graves' disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of GO is lower than in the past among patients with recent onset Graves' hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5-6% of all cases of GO. After an initial inflammatory (active) phase and a phase of stabilization (plateau phase), GO tends to improve and eventually inactivates (inactive or burnt-out phase). Minimal-to-mild GO often remits spontaneously, but complete <i>restitutio ad integrum</i> almost never occurs when GO is more than mild. Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them. Early diagnosis, control and removal of modifiable risk factors, early treatment of mild forms of GO may effectively limit the risk of progression to more severe forms, which have a profound and dramatic impact on the quality of life of affected individuals, and remain a therapeutic challenge, often requiring long-lasting and multiple medical and surgical therapies.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Bartalena, Piantanida, Gallo, Lai and Tanda.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bartalena</LastName>
            <ForeName>Luigi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Piantanida</LastName>
            <ForeName>Eliana</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gallo</LastName>
            <ForeName>Daniela</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Adriana</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanda</LastName>
            <ForeName>Maria Laura</ForeName>
            <Initials>ML</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrine Unit, Department of Medicine and Surgery, University of Insubria, ASST dei Sette Laghi, Varese, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073865" MajorTopicYN="N">Cigarette Smoking</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006980" MajorTopicYN="N">Hyperthyroidism</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Graves’ disease</Keyword>
        <Keyword MajorTopicYN="Y">Graves’ orbitopathy</Keyword>
        <Keyword MajorTopicYN="Y">TSH receptor antibodies</Keyword>
        <Keyword MajorTopicYN="Y">hyperthyroidism</Keyword>
        <Keyword MajorTopicYN="Y">hypothyroidism</Keyword>
        <Keyword MajorTopicYN="Y">radioiodine (131I) treatment</Keyword>
        <Keyword MajorTopicYN="Y">smoking</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>17</Day>
          <Hour>5</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33329408</ArticleId>
        <ArticleId IdType="pmc">PMC7734282</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2020.615993</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Bartalena L, Tanda ML.
Graves’ ophthalmopathy. N Engl J Med (2009) 360:994–1001.  10.1056/NEJMcp0806317
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMcp0806317</ArticleId>
            <ArticleId IdType="pubmed">19264688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. 
New insights into the pathogenesis and nonsurgical management of Graves’ orbitopathy. Nat Rev Endocrinol (2020) 16:104–16.  10.1038/s41574-019-0305-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41574-019-0305-4</ArticleId>
            <ArticleId IdType="pubmed">31889140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Diana T, Ponto KA, Kahaly GJ.
Thyrotropin receptor antibodies and Graves’ orbitopathy. J Endocrinol Invest (2020).  10.1007/s40618-020-01380-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01380-9</ArticleId>
            <ArticleId IdType="pubmed">32749654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicolì F, Lanzolla G, Mantuano M, Ionni I, Mazzi B, Leo M, et al. 
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest (2020).  10.1007/s40618-020-01353-y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01353-y</ArticleId>
            <ArticleId IdType="pubmed">32648002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. 
Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med (2017) 376:1748–61.  10.1056/NEJMoa1614949
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1614949</ArticleId>
            <ArticleId IdType="pmc">PMC5718164</ArticleId>
            <ArticleId IdType="pubmed">28467880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. 
Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med (2020) 382:341–52.  10.1056/NEJMoa1910434
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1910434</ArticleId>
            <ArticleId IdType="pubmed">31971679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lanzolla G, Ricci D, Nicolì F, Sabini E, Sframeli A, Brancatella A, et al. 
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves’ disease: results of a pilot study. J Endocrinol Invest (2020) 43:1759–68.  10.1007/s40618-020-01341-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01341-2</ArticleId>
            <ArticleId IdType="pubmed">32583374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bahn RS.
Graves’ ophthalmopathy. N Engl J Med (2010) 362:726–38.  10.1056/NEJMra0905750
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0905750</ArticleId>
            <ArticleId IdType="pmc">PMC3902010</ArticleId>
            <ArticleId IdType="pubmed">20181974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartley GB.
The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc (1994) 92:477–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1298522</ArticleId>
            <ArticleId IdType="pubmed">7886878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorf J, et al. 
Incidence of hyperthyroidism in Sweden. Eur J Endocrinol (2011) 165:899–905.  10.1530/EJE-11-0548
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-11-0548</ArticleId>
            <ArticleId IdType="pubmed">21908653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carlé A.
Incidence and clinical presentation of moderate to severe Graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab (2012) 97:2325–32.  10.1210/jc.2012-1275
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-1275</ArticleId>
            <ArticleId IdType="pmc">PMC3387399</ArticleId>
            <ArticleId IdType="pubmed">22518849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Hegedus L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, et al. 
Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis (2017) 12:72.  10.1186/s13023-017-0625-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13023-017-0625-1</ArticleId>
            <ArticleId IdType="pmc">PMC5397790</ArticleId>
            <ArticleId IdType="pubmed">28427469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. 
Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab (2013) 98:1443–9.  10.1210/jc.2012-3873
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3873</ArticleId>
            <ArticleId IdType="pubmed">23408569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, et al. 
PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group on Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol (2015) 99:1531–5.  10.1136/bjophthalmol-2015-306733
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjophthalmol-2015-306733</ArticleId>
            <ArticleId IdType="pubmed">25953846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zaletel K, Gaberscek S, Pirnat E.
Ten-year follow-up of thyroid epidemiology in Slovenia after increase in salt iodization. Croat Med J (2011) 52:615–21.  10.3325/cmj.2011.52.615
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3325/cmj.2011.52.615</ArticleId>
            <ArticleId IdType="pmc">PMC3195970</ArticleId>
            <ArticleId IdType="pubmed">21990079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lazarus JH.
Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab (2012) 26:273–9.  10.1016/j.beem.2011.10.05
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2011.10.05</ArticleId>
            <ArticleId IdType="pubmed">22632364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y.
Graves’ ophthalmopathy: epidemiology and natural history. Intern Med (2014) 53:353–60.  10.2169/internalmedicine.53.1518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.53.1518</ArticleId>
            <ArticleId IdType="pubmed">24583420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Kendall-Taylor P.
Natural history of thyroid associated ophthalmopathy. Thyroid (1998) 8:423–5.  10.1089/thy.1998.8.423
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.1998.8.423</ArticleId>
            <ArticleId IdType="pubmed">9623735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. 
Prevalence of thyroid eye disease in Graves’ disease: a meta-analysis and systematic review. Clin Endocrinol (Oxf) (2020).  10.1111/cen.14296
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.14296</ArticleId>
            <ArticleId IdType="pubmed">32691849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L.
Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Invest (2013) 36:444–9.  10.3275/8937
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3275/8937</ArticleId>
            <ArticleId IdType="pubmed">23587873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kozaki A, Inoue R, Komoto N, Maeda T, Inoue Y, Inoue T, et al. 
Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases. Optom Vis Sci (2010) 87:200–4.  10.1097/OPX.0b013e3181ce5702
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/OPX.0b013e3181ce5702</ArticleId>
            <ArticleId IdType="pubmed">20081550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Crombie AL, Matthews JN, Kendall-Taylor P.
Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) (1993) 38:367–72.  10.1111/j.1365-2265.1993.tb00516.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1993.tb00516.x</ArticleId>
            <ArticleId IdType="pubmed">8319368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Krassas GE, Segni M, Wiersinga WM.
Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol (2005) 53:515–21.  10.1530/eje.1.01991
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/eje.1.01991</ArticleId>
            <ArticleId IdType="pubmed">16189172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L.
Childhood Graves’ orbitopathy. In: Wiersinga WM, Kahaly GJ, editors. Graves’ orbitopathy. A multisciplinary approach – questions and anwers, 3rd
Basel: Karger;  (2017). 53:301–8. 10.1159/000475968
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000475968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A.
Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh) (1989) 120:473–8.  10.1530/acta.0.1200473
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/acta.0.1200473</ArticleId>
            <ArticleId IdType="pubmed">2718699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Zarkovic MP, Panagiotou GC, Azzolini C, Ayvaz G, Baldeschi L, et al. 
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study. J Endocrinol Invest (2020) 43
:1717–22.  10.1007/s40618-020-01258-w
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-020-01258-w</ArticleId>
            <ArticleId IdType="pmc">PMC7652741</ArticleId>
            <ArticleId IdType="pubmed">32474767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. 
Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab (2006) 91:4873–80.  10.1210/jc.2006-1402
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2006-1402</ArticleId>
            <ArticleId IdType="pubmed">16968788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tellez M, Cooper J, Edmonds C.
Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) (1992) 36:291–4.  10.1111/j.1365-2265.1992.tb01445.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1992.tb01445.x</ArticleId>
            <ArticleId IdType="pubmed">1563082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khong JJ, Finch S, De Silva C, Rylander S, Craig JE, Selva D, et al. 
Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy (ATOR) study. J Clin Endocrinol Metab (2016) 101:2716–20.  10.1210/jc.2015-4294
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2015-4294</ArticleId>
            <ArticleId IdType="pubmed">27055083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takakura A, Kirkeby K, Earle K, Silkiss RZ.
Predicting the development of orbitopathy in Graves thyroidopathy patients: the potential role of TSI testing. Ophthalm Plast Reconstr Surg (2015) 31:369–72.  10.1097/iop.0000000000000350
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/iop.0000000000000350</ArticleId>
            <ArticleId IdType="pubmed">25585304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stein JD, Childers D, Gupta S, Talwar N, Nan B, Lee BJ, et al. 
Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol (2015) 133:290–6.  10.1001/jamaophthalmol.2014.5103
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaophthalmol.2014.5103</ArticleId>
            <ArticleId IdType="pmc">PMC4495733</ArticleId>
            <ArticleId IdType="pubmed">25502604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, et al. 
Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol (2003) 148:491–5.  10.1530/eje.0.148049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/eje.0.148049</ArticleId>
            <ArticleId IdType="pubmed">12720530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Soroudi AE, Goldberg RA, McCann JD.
Prevalence of asymmetric exophthalmos in Graves orbitopathy. Ophthal Plast Reconstr Surg (2004) 20:224–5.  10.1097/01.iop.0000124675.80763.5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.iop.0000124675.80763.5</ArticleId>
            <ArticleId IdType="pubmed">15167731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Daumerie C, Duprez T, Boschi A.
Long-term multidisciplinary follow-up of unilateral thyroid-associatedorbitopathy. Eur J Intern Med (2008) 19:531–6.  10.1016/j.ejim.2008.01.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejim.2008.01.013</ArticleId>
            <ArticleId IdType="pubmed">19013383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eckstein AK, Losch C, Glowacka D, Schott M, Mann K, Esser J, et al. 
Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol (2009) 93:1052–6.  10.1136/bjo.2007.137265
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.2007.137265</ArticleId>
            <ArticleId IdType="pubmed">19221109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Strianese D, Piscopo R, Elefante A, Napoli M, Comune C, Baronissi I, et al. 
Unilateral proptosis in thyroid disease with subsequent contralateral involvement: retrospective follow-up study. BMC Ophthalmol (2013) 13:21.  10.1186/1471-2415-13-21
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2415-13-21</ArticleId>
            <ArticleId IdType="pmc">PMC3669615</ArticleId>
            <ArticleId IdType="pubmed">23721066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marinò M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R, et al. 
Orbital diseases mimicking Graves’ orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest (2020) 43:401–11.  10.1007/s40618-019-01141-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-019-01141-3</ArticleId>
            <ArticleId IdType="pubmed">31691261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rotondi M, Virili C, Pinto S, Coperchini F, Croce L, Brusca N, et al. 
The clinical phenotype of Graves’ disease occurring as an isolated condition or in association with other autoimmune diseases. J Endocrinol Invest (2020) 43:157–62.  10.1007/s40618-019-01094-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-019-01094-7</ArticleId>
            <ArticleId IdType="pubmed">31407208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khoo DH, Eng PH, Ho SC, Morgenthaler NG, Seah LL, Chee SP, et al. 
Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid (2000) 10:1093–100.  10.1089/thy.2000.10.1093
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2000.10.1093</ArticleId>
            <ArticleId IdType="pubmed">11201855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Li Y, Kim J, Diana T, Olivo PD, Kahaly GJ.
A novel bioassay for anti-thyrotrophin autoantibodies detects both thyroid-blocking and stimulating activities. Clin Exp Immunol (2013) 173:390–7.  10.1111/cei.12129
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12129</ArticleId>
            <ArticleId IdType="pmc">PMC3949626</ArticleId>
            <ArticleId IdType="pubmed">23647395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S, et al. 
Prevalence, phenotype, and psychological well-being in euthyroid/hypothyroid thyroid-associated orbitopathy. Thyroid (2015) 25:942–8.  10.1089/thy.2015.0031
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0031</ArticleId>
            <ArticleId IdType="pubmed">26244413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Smith TJ, Hegedus L.
Graves’ disease. N Engl J Med (2016) 375:1552–65.  10.1056/NEJMra1510030
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1510030</ArticleId>
            <ArticleId IdType="pubmed">27797318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF.
Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) (2000) 52:267–71.  10.1046/j.1365-2265.2000.00959.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2265.2000.00959.x</ArticleId>
            <ArticleId IdType="pubmed">10718823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J.
Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab (2016) 101:1998–2004.  10.1210/jc.2016-1220
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2016-1220</ArticleId>
            <ArticleId IdType="pubmed">26964732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Chiovato L.
Graves’-like orbitopathy: do not forget IgG4-related disease. J Endocrinol Invest (2014) 37:1233–5.  10.1007/s40618-014-0171-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-014-0171-9</ArticleId>
            <ArticleId IdType="pubmed">25194429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wiersinga WM, Bartalena L.
Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid (2002) 12:855–60.  10.1089/105072502761016476
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/105072502761016476</ArticleId>
            <ArticleId IdType="pubmed">12487767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A.
Relationship between Graves’ ophthalmopathy and type of treatment of Graves’ hyperthyroidism. Thyroid (1992) 2:171–8.  10.1089/thy.1992.2.171
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.1992.2.171</ArticleId>
            <ArticleId IdType="pubmed">1525588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R.
Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Intern Med (1990) 150:1098–101. 10.1001/archinte.150.5.1098
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archinte.150.5.1098</ArticleId>
            <ArticleId IdType="pubmed">1691908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. 
Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med (1998) 338:73–8.  10.1007/s40618-014-0171-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-014-0171-9</ArticleId>
            <ArticleId IdType="pubmed">9420337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rundle FF, Wilson CW.
Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci (1945) 5:177–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21011937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Pinchera A, Marcocci C.
Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev (2000) 21:168–99.  10.1210/edrv.21.2.0393
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/edrv.21.2.0393</ArticleId>
            <ArticleId IdType="pubmed">10782363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Selva D, Chen C, King G.
Late reactivation of thyroid orbitopathy. Clin Exp Ophthalmol (2004) 32:46–50.  10.1046/j.1442-9071.2004.00756.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1442-9071.2004.00756.x</ArticleId>
            <ArticleId IdType="pubmed">14746591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Potgieser PW, Wiersinga WM, Regensburg NI, Mourits MP.
Some studies on the natural history of Graves’ orbitopathy: increase in orbital fat is a rather late phenomenon. Eur J Endocrinol (2015) 173:149–53.  10.1530/EJE-14-1140
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-14-1140</ArticleId>
            <ArticleId IdType="pubmed">26142100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. 
The 2016 European Thyroid Association /European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J (2016) 5:9–26.  10.1159/000443828
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000443828</ArticleId>
            <ArticleId IdType="pmc">PMC4836120</ArticleId>
            <ArticleId IdType="pubmed">27099835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Crombie AL, Kendall-Taylor P.
Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) (1995) 42:45–50.  10.1111/j.1365-2265.1995.tb02597.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.1995.tb02597.x</ArticleId>
            <ArticleId IdType="pubmed">7889631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Noth D, Gebauer M, Muller B, Burgi U, Diem P.
Graves’ ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly (2001) 131:603–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11820071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menconi F, Profilo MA, Leo M, Sisti E, Altea MA, Rocchi R, et al. 
Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid (2014) 24:60–6.  10.1089/thy.2013.0240
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2013.0240</ArticleId>
            <ArticleId IdType="pmc">PMC3887427</ArticleId>
            <ArticleId IdType="pubmed">23980907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menconi F, Leo M, Sabini E, Mautone T, Nardi M, Sainato A, et al. 
Natural history of Graves’ orbitopathy after treatment. Endocrine (2017) 57:226–33.  10.1007/s12020-016-1136-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-016-1136-x</ArticleId>
            <ArticleId IdType="pubmed">27709471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brix TH, Hegedus L.
Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf) (2012) 76:457–64.  10.1111/j.1365-2265.2011.04318.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2011.04318.x</ArticleId>
            <ArticleId IdType="pubmed">22168537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tomer Y.
Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol (2014) 9:147–56.  10.1146/annurev-pathol-012513-104713
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pathol-012513-104713</ArticleId>
            <ArticleId IdType="pmc">PMC4128637</ArticleId>
            <ArticleId IdType="pubmed">24460189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P.
Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest (2015) 38:283–94.  10.1007/s40618-014-0214-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-014-0214-2</ArticleId>
            <ArticleId IdType="pubmed">25421156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yin X, Latif R, Bahn R, Davies TF.
Genetic profiling in Graves’ disease: further evidence for lack of a distinct genetic contribution to Graves’ orbitopathy. Thyroid (2012) 22:730–5.  10.1089/thy.2012.0007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2012.0007</ArticleId>
            <ArticleId IdType="pmc">PMC3387758</ArticleId>
            <ArticleId IdType="pubmed">22663548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jurecka-Lubieniecka B, Ploski R, Kula D, Szymanski K, Bednarczuk T, Ambroziak U, et al. 
Association between polymorphisms in the TSHR gene and Graves’ orbitopathy. PLoS One (2014) 9:e102653.  10.1371/journal.pone.0102653
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0102653</ArticleId>
            <ArticleId IdType="pmc">PMC4111286</ArticleId>
            <ArticleId IdType="pubmed">25061884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L.
Prevention of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab (2012) 26:371–9.  10.1016/j.beem.2011.09.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2011.09.004</ArticleId>
            <ArticleId IdType="pubmed">22632372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wiersinga WM.
Smoking and thyroid. Clin Endocrinol (Oxf) (2013) 79:145–51.  10.1111/cen.12222
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12222</ArticleId>
            <ArticleId IdType="pubmed">23581474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Piantanida E.
Cigarette smoking: number one enemy for Graves’ ophthalmopathy. Pol Arch Med Wewn (2016) 126:725–6.  10.20452/pamw.3592
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20452/pamw.3592</ArticleId>
            <ArticleId IdType="pubmed">27872448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, et al. 
More on smoking habits and Graves’ ophthalmopathy. J Endocrinol Invest (1989) 12:733–7.  10.1007/BF03350047
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03350047</ArticleId>
            <ArticleId IdType="pubmed">2614012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prummel MF, Wiersinga WM.
Smoking and risk of Graves’ disease. JAMA (1993) 269:479–82. 10.1001/jama.269.4.479
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.269.4.479</ArticleId>
            <ArticleId IdType="pubmed">8419666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pfeilschifter J, Ziegler R.
Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime tobacco consumption. Clin Endocrinol (Oxf) (1996) 45:477–81.  10.1046/j.1365-2265.1996.8220832.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1365-2265.1996.8220832.x</ArticleId>
            <ArticleId IdType="pubmed">8959089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell’Unto E, Bartolomei MP, et al. 
Cigarette smoking and treatment outcomes in Graves’ ophthalmopathy. Ann Intern Med (1998) 129:632–5.  10.7326/0003-4819-129-8-199810150-00010
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-129-8-199810150-00010</ArticleId>
            <ArticleId IdType="pubmed">9786811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eckstein AK, Quadbeck B, Mueller G, Rettemeier AW, Hoermann R, Mann K, et al. 
Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol (2003) 73:773–6.  10.1136/bjo.87.6.773
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.87.6.773</ArticleId>
            <ArticleId IdType="pmc">PMC1771717</ArticleId>
            <ArticleId IdType="pubmed">12770979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Traisk F, Tallstedt F, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, et al. 
Thyroid-associated ohthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab (2009) 94:3700–7.  10.1136/bjo.87.6.773
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bjo.87.6.773</ArticleId>
            <ArticleId IdType="pubmed">19723755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J.
A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab (2005) 90:5321–3.  10.1210/jc.2005-0507
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2005-0507</ArticleId>
            <ArticleId IdType="pubmed">15985483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. 
Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med (1992) 326:1733–8.  10.1056/NEJM199206253262603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199206253262603</ArticleId>
            <ArticleId IdType="pubmed">1489388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Tanda ML, Piantanida E, Lai A.
Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. Biofactors (2003) 19:155–63.  10.1002/biof.5520190308
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biof.5520190308</ArticleId>
            <ArticleId IdType="pubmed">14757966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ.
A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab (2010) 95:2123–31.  10.1210/jc.2009-2470
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-2470</ArticleId>
            <ArticleId IdType="pubmed">20237164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, et al. 
High serum cholesterol is a novel risk factor for Graves’ orbitopathy: results of a cross-sectional study. Thyroid (2018) 28:386–94.  10.1089/thy.2017.0430
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0430</ArticleId>
            <ArticleId IdType="pubmed">29336220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lanzolla G, Sabini E, Profilo MA, Mazzi B, Sframeli A, Rocchi R, et al. 
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study. J Endocrinol Invest (2018) 41:1417–23.  10.1007/s40618-018-0915-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-018-0915-z</ArticleId>
            <ArticleId IdType="pubmed">29923059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH.
European Thyroid Association Guideline for the management of Graves? Hyperthyroidism. Eur Thyroid J (2018) 7:167–86.  10.1159/000490384
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000490384</ArticleId>
            <ArticleId IdType="pmc">PMC6140607</ArticleId>
            <ArticleId IdType="pubmed">30283735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A.
Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine treatment for hyperthyroidism. N Engl J Med (1989) 321:1349–52.  10.1056/NEJM198911163212001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198911163212001</ArticleId>
            <ArticleId IdType="pubmed">2811943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vannucchi G, Covelli D, Campi I, Currò N, Dazzi D, Rodari M, et al. 
Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease undergoing radioiodine ablation: a prospective randomized control trial study. Thyroid (2019) 29:1828–33.  10.1089/thy.2019.0150
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0150</ArticleId>
            <ArticleId IdType="pubmed">31860407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, et al. 
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab (2010) 95:1333–7.  10.1210/jc.2009-213
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-213</ArticleId>
            <ArticleId IdType="pubmed">20061414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosetti S, Tanda ML, Veronesi G, Masiello E, Premoli P, Gallo D, et al. 
Oral steroid prophylaxis for Graves’ orbitopathy after radioactive iodine treatment for Graves’ disease is not only effective, but also safe. J Endocrinol Invest (2020) 43:381–3.  10.1007/s40618-019-01126-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40618-019-01126-2</ArticleId>
            <ArticleId IdType="pubmed">31587179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. 
Selenium and the course of mild Graves’ ophthalmopathy. N Engl J Med (2011) 364:1920–31.  10.1056/nejmoa1012985
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/nejmoa1012985</ArticleId>
            <ArticleId IdType="pubmed">21591944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, et al. 
Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab (2006) 91:3464–70.  10.1210/jc.-2005-2813
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.-2005-2813</ArticleId>
            <ArticleId IdType="pubmed">16835285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Khoo DHC, Ho SC, Seah LL, Fong KS, Tal ES, Chee SP, et al. 
The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves’ disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid (1999) 9:1175–80.  10.1089/thy.1999.9.1175
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.1999.9.1175</ArticleId>
            <ArticleId IdType="pubmed">10646655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goh SH, Ho SC, Seah LL, Fong KS, Khoo DHC.
Thyroid autoantibody profile in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf) (2004) 60:607.  10.1111/j.1365-2265.2004.02033.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2004.02033.x</ArticleId>
            <ArticleId IdType="pubmed">15104563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O.
TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol (2008) 158:69–75.  10.1530/EJE-07-0450
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-07-0450</ArticleId>
            <ArticleId IdType="pubmed">18166819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wiersinga WM, Zarkovic M, Bartalena L, Donati S, Perros P, Okosieme O, et al. 
Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol (2018) 178:635–43.  10.1530/EJE-18-0039
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-18-0039</ArticleId>
            <ArticleId IdType="pubmed">29650691</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
